374794-91-9

Basic information

• Product Name: tert-butyl 4-(3-ethoxy-3-oxopropyl)-4-hydroxypiperidine-1-carboxylate
• Synonyms: tert-Butyl-4-(3-ethoxy-3-oxopropyl)-4-hydroxypiperidin-1-carboxylat
• CAS NO: 374794-91-9
• Molecular Formula: C₁₅H₂₇NO₅
• Molecular Weight: 301.3786
• Mol File: 374794-91-9.mol

Chemical Properties

• Boiling Point: 390.238°C at 760 mmHg
• Flash Point: 189.809°C
• Density: 1.113g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.488
• CAS DataBase Reference: tert-butyl 4-(3-ethoxy-3-oxopropyl)-4-hydroxypiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(3-ethoxy-3-oxopropyl)-4-hydroxypiperidine-1-carboxylate(374794-91-9)
• EPA Substance Registry System: tert-butyl 4-(3-ethoxy-3-oxopropyl)-4-hydroxypiperidine-1-carboxylate(374794-91-9)

Safety Data

• Hazardous Substances Data: 374794-91-9(Hazardous Substances Data)

Upstream product

• 623-47-2 propynoic acid ethyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 374794-90-8 1,1-dimethylethyl 4-(3-ethoxy-3-oxo-1-propynyl)-4-hydroxy-1-piperidinecarboxylate 

Downstream Products

• 374794-88-4 tert-butyl 4-hydroxy-4-(3-hydroxypropyl)piperidine-1-carboxylate 
• 374794-89-5 1,1-dimethylethyl 1-oxa-8-azaspiro[4,5]decane-8-carboxylate 
• 167364-29-6 1-oxa-8-aza-spiro[4.5]decan-2-one 
• 176-92-1 4-dioxa-8-azaspiro[4.5]decane 

Relevant articles and documents

TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS

The present invention relates to the compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and W are as defined herein, and pharmaceutically acceptable salts thereof; the compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

Cyclohexane derivatives and their use as therapeutic agents

The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

4,4-Disubstituted cyclohexylamine NK1 receptor antagonists II

A series of novel 4,4-disubstituted cyclohexylamines as NK1 receptor antagonists is described: modifications to the amine moiety retain NK1 receptor binding affinity whilst disrupting IKr affinity.